The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease.

The search for a biomarker for Parkinson's disease (PD) has led to a surge in literature describing peripheral α-synuclein (aSyn) in both biofluids and biopsy/autopsy tissues. Despite encouraging results, attempts to capitalize on this promise have fallen woefully short. The Systemic Synuclein Sampling Study (S4) is uniquely designed to identify a reproducible diagnostic and progression biomarker for PD. S4 will evaluate aSyn in multiple tissues and biofluids within the same subject and across the disease spectrum to identify the optimal biomarker source and provide vital information on the evolution of peripheral aSyn throughout the disease. Additionally, S4 will correlate the systemic aSyn profile with an objective measure of nigrostriatal dopaminergic function furthering our understanding of the pathophysiological progression of PD.

[1]  C. Adler,et al.  Multicenter Assessment of Immunohistochemical Methods for Pathological Alpha-Synuclein in Sigmoid Colon of Autopsied Parkinson's Disease and Control Subjects. , 2016, Journal of Parkinson's disease.

[2]  M. Esiri,et al.  Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies , 2016, Annals of clinical and translational neurology.

[3]  R. Freeman,et al.  The diagnostic discrimination of cutaneous α-synuclein deposition in Parkinson disease , 2016, Neurology.

[4]  E. Tolosa,et al.  Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study , 2016, The Lancet Neurology.

[5]  Tessandra H Stewart,et al.  Alpha‐Synuclein as a Biomarker for Parkinson's Disease , 2016, Brain pathology.

[6]  T. Beach,et al.  Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies , 2016, Acta neuropathologica communications.

[7]  A. Berardelli,et al.  Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson’s Disease , 2016, PloS one.

[8]  P. Svenningsson,et al.  Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders , 2016, Journal of neurochemistry.

[9]  P. Cortelli,et al.  Skin nerve misfolded α‐synuclein in pure autonomic failure and Parkinson disease , 2016, Annals of neurology.

[10]  C. Adler,et al.  Peripheral Synucleinopathy in Early Parkinson's Disease: Submandibular Gland Needle Biopsy Findings , 2016, Movement disorders : official journal of the Movement Disorder Society.

[11]  L. Parkkinen,et al.  Gut Feelings About α‐Synuclein in Gastrointestinal Biopsies: Biomarker in the Making? , 2016, Movement disorders : official journal of the Movement Disorder Society.

[12]  B. Mollenhauer,et al.  Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies , 2015, Brain : a journal of neurology.

[13]  A. Lipp,et al.  Phosphorylated α-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy. , 2015, Brain : a journal of neurology.

[14]  E. Tolosa,et al.  Cutaneous autonomic denervation in Parkinson’s disease , 2015, Journal of Neural Transmission.

[15]  Fang-fei Li,et al.  Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson’s disease , 2015, Neuroscience Letters.

[16]  A. Kakita,et al.  Quantitative correlation between cardiac MIBG uptake and remaining axons in the cardiac sympathetic nerve in Lewy body disease , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[17]  S. Yagihashi,et al.  Clinical Utility of Skin Biopsy in Differentiating between Parkinson's Disease and Multiple System Atrophy , 2015, Parkinson's disease.

[18]  R. Wade-Martins,et al.  Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson’s disease brain , 2015, Brain : a journal of neurology.

[19]  L. Hazrati,et al.  Colonic mucosal α-synuclein lacks specificity as a biomarker for Parkinson disease , 2015, Neurology.

[20]  M. Al-Nimer,et al.  Saliva α-Synuclein and A High Extinction Coefficient Protein: A Novel Approach in Assessment Biomarkers of Parkinson's Disease , 2014, North American journal of medical sciences.

[21]  H. Shill,et al.  Low clinical diagnostic accuracy of early vs advanced Parkinson disease , 2014, Neurology.

[22]  Thomas G. Beach,et al.  Quantitative Measurement of Intact Alpha-Synuclein Proteoforms from Post-Mortem Control and Parkinson's Disease Brain Tissue by Intact Protein Mass Spectrometry , 2014, Scientific Reports.

[23]  E. Tolosa,et al.  Multiple organ involvement by alpha‐synuclein pathology in Lewy body disorders , 2014, Movement disorders : official journal of the Movement Disorder Society.

[24]  J. Volkmann,et al.  Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology , 2014, Acta Neuropathologica.

[25]  Agostino Baruzzi,et al.  Skin nerve &agr;-synuclein deposits: A biomarker for idiopathic Parkinson disease , 2014, Neurology.

[26]  L. Hazrati,et al.  Alimentary, my dear Watson? The challenges of enteric α‐synuclein as a Parkinson's disease biomarker , 2014, Movement disorders : official journal of the Movement Disorder Society.

[27]  H. Shill,et al.  Submandibular gland needle biopsy for the diagnosis of Parkinson disease , 2014, Neurology.

[28]  R. Barker,et al.  Anti-amyloid Compounds Inhibit α-Synuclein Aggregation Induced by Protein Misfolding Cyclic Amplification (PMCA)* , 2014, The Journal of Biological Chemistry.

[29]  R. Freeman,et al.  α-Synuclein in cutaneous autonomic nerves , 2013, Neurology.

[30]  L. Lannfelt,et al.  Monoclonal antibodies selective for α‐synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α‐synuclein transgenic mice with the disease‐causing A30P mutation , 2013, Journal of neurochemistry.

[31]  H. Shill,et al.  Submandibular gland biopsy for the diagnosis of Parkinson disease. , 2013, Journal of neuropathology and experimental neurology.

[32]  G. Deuschl,et al.  Expression pattern and localization of alpha-synuclein in the human enteric nervous system , 2012, Neurobiology of Disease.

[33]  G. Muntané,et al.  α-synuclein phosphorylation and truncation are normal events in the adult human brain , 2012, Neuroscience.

[34]  S. Cheon,et al.  Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease , 2011, Journal of clinical neurology.

[35]  D. Goodlett,et al.  Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. , 2011, Brain : a journal of neurology.

[36]  K. Satoh,et al.  Real-time quaking-induced conversion , 2011, Prion.

[37]  T. Tokuda,et al.  Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease , 2010, Neurology.

[38]  W. Schulz-Schaeffer.  The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia , 2010, Acta Neuropathologica.

[39]  H. Shill,et al.  Incidental Lewy body disease: Clinical comparison to a control cohort , 2010, Movement disorders : official journal of the Movement Disorder Society.

[40]  H. Shill,et al.  Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders , 2010, Acta Neuropathologica.

[41]  S. Murayama,et al.  α-SYNUCLEIN ACCUMULATION IN SKIN NERVE FIBERS REVEALED BY SKIN BIOPSY IN PURE AUTONOMIC FAILURE , 2010, Neurology.

[42]  Yasuo Miki,et al.  Clinical availability of skin biopsy in the diagnosis of Parkinson's disease , 2010, Neuroscience Letters.

[43]  H. Shill,et al.  Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction , 2009, Acta Neuropathologica.

[44]  T. Iwatsubo,et al.  Lewy Body Pathology Involves Cutaneous Nerves , 2008, Journal of neuropathology and experimental neurology.

[45]  Satoshi Orimo,et al.  Axonal α-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease , 2008 .

[46]  R. Barbour,et al.  Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood , 2008, Neurodegenerative Diseases.

[47]  H. Braak,et al.  Parkinson's disease: a dual‐hit hypothesis , 2007, Neuropathology and applied neurobiology.

[48]  M. Horne,et al.  Plasma α-synuclein is decreased in subjects with Parkinson's disease , 2007, Experimental Neurology.

[49]  B. Boeve,et al.  α-Synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals , 2006, Neurology.

[50]  H. Braak,et al.  Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology , 2006, Neuroscience Letters.

[51]  D. Allsop,et al.  Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  P. Lee,et al.  The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy , 2006, Journal of Neural Transmission.

[53]  I. Alafuzoff,et al.  Widespread and abundant α‐synuclein pathology in a neurologically unimpaired subject , 2005 .

[54]  Satoshi Orimo,et al.  Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease , 2005, Acta Neuropathologica.

[55]  Udo Rüb,et al.  Where Does Parkinson Disease Pathology Begin in the Brain? , 2002, Journal of neuropathology and experimental neurology.

[56]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[57]  C. Adler,et al.  The Search for a Peripheral Biopsy Indicator of &agr;-Synuclein Pathology for Parkinson Disease , 2017, Journal of neuropathology and experimental neurology.

[58]  H. Shill,et al.  Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders. , 2016, Journal of Parkinson's disease.

[59]  B. Mollenhauer,et al.  The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. , 2016, Biomarkers in medicine.

[60]  K. Satoh,et al.  A highly sensitive assay for prion detection , 2011 .

[61]  H. Braak,et al.  The Dual Hit Theory Revisited , 2009 .

[62]  M. Horne,et al.  Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. , 2007, Experimental neurology.

[63]  I. Alafuzoff,et al.  Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject. , 2005, Neuropathology : official journal of the Japanese Society of Neuropathology.

[64]  R A Crowther,et al.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.